IN-VIVO EVALUATION OF SPRAY FORMULATIONS OF HUMAN INSULIN FOR NASAL DELIVERY

被引:40
|
作者
DONDETI, P [1 ]
ZIA, HS [1 ]
NEEDHAM, TE [1 ]
机构
[1] UNIV RHODE ISL,COLL PHARM,DEPT PHARMACEUT,KINGSTON,RI 02881
关键词
INSULIN; HUMAN; NASAL ADMINISTRATION; SPRAY FORMULATION; BIOADHESIVE POLYMER; MICROCRYSTALLINE CELLULOSE; PLASTOID; AMMONIUM GLYCYRRHIZINATE; GLYCYRRHETINIC ACID; SODIUM TAUROCHOLATE;
D O I
10.1016/0378-5173(95)00045-K
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There are many ongoing investigations to improve the nasal bioavailability of peptide and protein formulations. The presence of bioadhesive polymers in nasal formulations may increase the residence time of the drugs in the nasal cavity. A combination of bioadhesive polymers with permeation enhancers would seem to further improve nasal bioavailability. In this study, insulin spray formulations containing two bioadhesive polymers (1.5% w/v microcrystalline cellulose (MCC) and 70% w/w Plastoid L50) alone or in combination with the enhancers such as sodium taurocholate (ST), ammonium glycyrrhizinate (AG) or glycyrrhetinic acid (GA) at 1% w/v level, were evaluated in diabetic rabbits. A total volume of 100 mu l of freshly prepared insulin formulation was sprayed into the nasal cavity of each diabetic rabbit. Glucose levels were monitored using a blood glucose assay and serum insulin levels were analyzed using RIA. 5 U/kg insulin in the MCC suspension alone resulted in an absolute bioavailability of 1.96% while Plastoid L50 alone resulted in 2.25% absolute bioavailability. Insulin in the MCC suspension and ST, AG or GA resulted in 8.36, 7.83 and 2.15% bioavailability, respectively. The same formulations produced a hypoglycemic effect in terms of total glucose reductions of 39.12, 15.96 and 9.36% and the maximal decreases in glucose levels were 58.37, 21.8 and 18.61%, respectively. The Plastoid formulation containing 1% ST provided nasal insulin bioavailability of 5.9% with a total glucose reduction of 17.03% and a maximal glucose decrease of 26.56%. Insulin spray formulations containing 1% ST alone and 1% AG alone resulted in bioavailabilities of 7.25 and 3.57%, respectively. These same sprays provided total glucose reductions of 25.08 and 16.97% with maximal glucose decreases of 44.56 and 19.81%, respectively. The presence of benzalkonium chloride and 2-phenylethanol as preservatives in the MCC suspension resulted in higher insulin absorption than the same formulation without preservatives (6.31% vs 1.96%).
引用
收藏
页码:91 / 105
页数:15
相关论文
共 50 条
  • [1] CHARACTERISATION OF A HUMAN NASAL SPRAY FOR NOSE TO BRAIN DELIVERY OF INSULIN
    Wingrove, Jed
    Swedrowska, Magda
    Parry, Mark
    Ramjeeawon, Mervin
    Taylor, David
    Gauthier, Gregoire
    Zelaya, Fernando
    Forbes, Ben
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2018, 31 (02) : A20 - A20
  • [2] In vivo evaluation of a nasal insulin delivery system based on thiolated chitosan
    Krauland, Alexander H.
    Leitner, Verena M.
    Grabovac, Vjera
    Bernkop-Schnuerch, Andreas
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (11) : 2463 - 2472
  • [3] OPHTHALMIC AND NASAL DELIVERY OF INSULIN FROM OILY SUSPENSIONS IN RABBITS IN-VITRO AND IN-VIVO
    YAMAMOTO, T
    MAITANI, Y
    MACHIDA, Y
    NAGAI, T
    STP PHARMA SCIENCES, 1994, 4 (02): : 133 - 138
  • [4] IN-VITRO, IN-VIVO EVALUATION OF PHENFORMIN FORMULATIONS
    SIMMONS, DL
    LEGORE, AA
    KLAPKA, M
    JOSHI, NN
    CANADIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1973, 8 (04): : 139 - 141
  • [5] In-Vivo Evaluation of a Noninvasive Transdermal Insulin Delivery System Utilizing Ultrasound Transducers
    Al-Bataineh, Osama M.
    Lweesy, Khaldon
    Fraiwan, Loay
    JOURNAL OF MEDICAL IMAGING AND HEALTH INFORMATICS, 2011, 1 (03) : 267 - 270
  • [6] CONTRIBUTION OF PORTAL INSULIN DELIVERY TO THE ASSESSMENT OF INSULIN SENSITIVITY IN-VIVO
    STEIL, GM
    REBRIN, K
    BERGMAN, RN
    DIABETOLOGIA, 1995, 38 : A125 - A125
  • [7] DEXTRAN MICROSPHERES AS A POTENTIAL NASAL DRUG-DELIVERY SYSTEM FOR INSULIN - IN-VITRO AND IN-VIVO PROPERTIES
    PERESWETOFFMORATH, L
    EDMAN, P
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 124 (01) : 37 - 44
  • [8] Development and in-vivo evaluation of insulin-loaded chitosan phthalate microspheres for oral delivery
    Ubaidulla, Udhumansha
    Khar, Roop Kishan
    Ahmed, Farhan Jalees
    Panda, Amulya Kumar
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2007, 59 (10) : 1345 - 1351
  • [9] Microencapsulated chitosan nanoparticles for pulmonary protein delivery: In vivo evaluation of insulin-loaded formulations
    Al-Qadi, S.
    Grenha, A.
    Carrion-Recio, D.
    Seijo, B.
    Remunan-Lopez, C.
    JOURNAL OF CONTROLLED RELEASE, 2012, 157 (03) : 383 - 390
  • [10] EVALUATION OF A NOVEL COLONIC DELIVERY DEVICE IN-VIVO
    QUADROS, E
    CASSIDY, J
    HIRSCHBERG, Y
    OBERLE, R
    CARR, J
    SAVASTANO, L
    STP PHARMA SCIENCES, 1995, 5 (01): : 77 - 82